At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzum-Based Neoadjuvant Therapy
In Brief
A Phase 2 clinical trial evaluating Copper Cu 64-DOTA-Trastuzumab, Laboratory Biomarker Analysis, and 4 other interventions for HER2 Positive Breast Carcinoma and 3 related conditions. Active but no longer recruiting, targeting 18 participants across 1 site.
Detailed Summary
This phase II trial studies how well copper Cu64-DOTA-trastuzumab positron emission tomography (PET) works in predicting response to treatment with trastuzumab and pertuzumab before surgery in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread from where it started to nearby tissue or lymph nodes. Diagnostic procedures, such as copper Cu 64 DOTA-trastuzumab PET, may help predict a patient's response to trastuzumab and pertuzumab before surgery in patients with locally advanced HER2 positive breast cancer.
Study Details
Timeline
Interventions
Given IV
Correlative studies
Given IV
Undergo PET
Undergo surgery
Given IV